{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:41:18Z","timestamp":1785260478736,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.lungcan.2025.108590","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:19:50Z","timestamp":1747826390000},"page":"108590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Risk of lung injury with immune checkpoint inhibitors after talc pleurodesis: A retrospective study"],"prefix":"10.1016","volume":"204","author":[{"given":"Susumu","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Yanagimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Saida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kushiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Miyabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2025.108590_b0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12931-024-02684-7","article-title":"Malignant pleural effusion: current understanding and therapeutic approach","volume":"25","author":"Gonnelli","year":"2024","journal-title":"Respir Res."},{"key":"10.1016\/j.lungcan.2025.108590_b0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","article-title":"Management of malignant pleural effusions. An Official ATS\/STS\/STR Clinical Practice Guideline","volume":"198","author":"Feller-Kopman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lungcan.2025.108590_b0015","unstructured":"Lung Cancer Treatment Guidelines 2024 Edition. Edited by the Japan Lung Cancer Society."},{"key":"10.1016\/j.lungcan.2025.108590_b0020","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ejcts.2005.12.025","article-title":"The evidence on the effectiveness of management for malignant pleural effusion","volume":"29","author":"Tan","year":"2006","journal-title":"Eur. J. Cardiothorac Surg."},{"key":"10.1016\/j.lungcan.2025.108590_b0025","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2169\/internalmedicine.56.7464","article-title":"Interstitial lung disease after pleurodesis for malignant pleural effusion","volume":"56","author":"Yokoe","year":"2017","journal-title":"Intern. Med."},{"key":"10.1016\/j.lungcan.2025.108590_b0030","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00408-007-9041-y","article-title":"Pleural mesothelial cells mediate inflammatory and profibrotic responses in talc-induced pleurodesis","volume":"185","author":"Acencio","year":"2007","journal-title":"Lung"},{"key":"10.1016\/j.lungcan.2025.108590_b0035","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1164\/rccm.200311-1579OC","article-title":"Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size","volume":"170","author":"Maskell","year":"2004","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"10.1016\/j.lungcan.2025.108590_b0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/resp.12328","article-title":"Interventional therapies for malignant pleural effusions: the present and the future","volume":"19","author":"Thomas","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.lungcan.2025.108590_b0045","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(07)60708-9","article-title":"Safety of pleurodesis with talc poudrage in malignant pleural effusion","volume":"369","author":"Janssen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2025.108590_b0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13019-021-01475-1","article-title":"Complications of thoracoscopic talc insufflation for the treatment of malignant pleural effusions: a meta-analysis","volume":"16","author":"Zhang","year":"2021","journal-title":"J. Cardiothoracic Surg."},{"key":"10.1016\/j.lungcan.2025.108590_b0055","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jjco\/hyy020","article-title":"Sterilized talc pleurodesis for malignant pleural effusions: a Phase II study for investigational new drug application in Japan","volume":"48","author":"Saka","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108590_b0060","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108590_b0065","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1200\/JCO.21.01611","article-title":"Inoperable early-stage non-small-cell lung cancer: stereotactic ablative radiotherapy and rationale for systemic therapy","volume":"40","author":"Daly","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108590_b0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.lungcan.2021.11.006","article-title":"Immune checkpoint inhibitor therapy for malignant pleural mesothelioma","volume":"162","author":"Nowak","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108590_b0075","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108590_b0080","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108590_b0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108590_b0090","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108590_b0095","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1111\/cas.15117","article-title":"Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: postmarketing surveillance","volume":"112","author":"Yamamoto","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2025.108590_b0100","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1111\/cas.14647","article-title":"First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset","volume":"111","author":"Satouchi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2025.108590_b0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.03.016","article-title":"Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-na\u00efve patients with non-squamous non-small cell lung cancer","volume":"150","author":"Fujimoto","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108590_b0110","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.resinv.2017.11.006","article-title":"Severe interstitial pneumonia associated with anti-PD-1 immune checkpoint antibody after talc slurry pleurodesis","volume":"56","author":"Sakata","year":"2018","journal-title":"Respir Investig."},{"key":"10.1016\/j.lungcan.2025.108590_b0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/resp.13192","article-title":"Old age and underlying interstitial abnormalities are risk factors for development of ARDS after pleurodesis using limited amount of large particle size talc","volume":"23","author":"Shinno","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.lungcan.2025.108590_b0120","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108590_b0125","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MCP.0000000000000689","article-title":"Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer","volume":"26","author":"Shannon","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.lungcan.2025.108590_b0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2025.108590_b0135","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.lungcan.2025.108590_b0140","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 Part 1 Trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108590_b0145","unstructured":"The Japanese Respiratory Society, Committee for the Creation of the Second Edition of the Guidelines for the Diagnosis and Treatment of Drug-Induced Lung Injury. Guidelines for the Diagnosis and Treatment of Drug-Induced Lung Injury, 2nd Edition [2018]."},{"key":"10.1016\/j.lungcan.2025.108590_b0150","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/1759-7714.12759","article-title":"Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease","volume":"9","author":"Kanai","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.lungcan.2025.108590_b0155","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T20:23:05Z","timestamp":1753993385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225004829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":31,"alternative-id":["S0169500225004829"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108590","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of lung injury with immune checkpoint inhibitors after talc pleurodesis: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108590"}}